Bevacizumab Plus FOLFIRI as Second-Line Treatment for Advanced Neuroendocrine Carcinoma After Failure of Platinum–Etoposide Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
Lancet Oncol 2023 Feb 02;[EPub Ahead of Print], T Walter, A Lievre, R Coriat, D Malka, F Elhajbi, F Di Fiore, O Hentic, D Smith, V Hautefeuille, G Roquin, M Perrier, L Dahan, V Granger, I Sobhani, L Mineur, P Niccoli, E Assenat, JY Scoazec, K Le Malicot, C Lepage, C Lombard-BohasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.